Shareholders to Vote on 10x Authorized Share Increase and Potential 61% Control Shift at GT Biopharma

summarizeSummary

GT Biopharma's special meeting proxy seeks approval to increase authorized shares 10x to 250 million and to permit Series M preferred conversions and warrant exercises that could give private investors up to 61% voting control.

check_boxKey Events · Corporate Governance and Compliance · GTBP

• 10x Authorized Share Increase Proposed

  Proposal No. 2 would increase authorized common shares from 25,000,000 to 250,000,000, expanding authorized but unissued shares from 11.3 million to 236.3 million.

• Potential 61% Voting Control Shift

  If all Series M preferred shares convert and all warrants exercise, Private Placement Investors would hold approximately 61% of voting power, up from 44% with conversion alone.

• Nasdaq Rule 5635 Approval Sought

  Proposal No. 3 seeks stockholder approval for issuance of 19.99% or more of outstanding shares, required because the private placement could trigger a change of control under Nasdaq rules.

• Conversion Price Set at $6.10

  Series M preferred stock converts at $6.10 per share, with warrants exercisable at $6.10, subject to adjustment and a floor price of $1.282 if Nasdaq requires.

auto_awesomeAnalysis · GTBP · Life Sciences

Shareholders are being asked to approve a 10-fold increase in authorized common shares, from 25 million to 250 million, along with the Series M preferred stock conversion and warrant exercises that could hand Private Placement Investors up to 61% of voting power. The $6.10 conversion price matches today's stock price, but the real story is the massive dilution headroom being created — authorized but unissued shares would jump from 11.3 million to 236.3 million. For a company that just regained Nasdaq compliance after a 1-for-25 reverse split, this is a critical governance moment: shareholders are being asked to approve a structure that could fundamentally alter control of the company.